Elsamitrucin

Drug Profile

Elsamitrucin

Alternative Names: BBM 2478A; BMY 28090; Elsamicin A; NSC 369327; SPI-28090

Latest Information Update: 14 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Spectrum Pharmaceuticals
  • Class Aminoglycosides; Benzopyrans; Cytostatic antibiotics
  • Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours
  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Apr 2016 No recent reports on development identified - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in USA (IV)
  • 21 Apr 2011 Elsamitrucin is available for licensing in World (excluding USA) as of 21 Apr 2011. http://www.spectrumpharm.com/
  • 21 Apr 2011 Phase-I clinical trials in late-stage Solid tumours (in combination with paclitaxel) in USA (IV) before April 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top